{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 2. PART 2 SCHEDULE OF ASSESSMENTS', 'Period', 'Treatment Period', 'Follow-Up Period', 'Visit 6B', 'Visit 7', 'Visit 8', 'Visits 9-13', 'Phone Call', 'Visit 14', '(Week 28)', '(Week 36)', '(Week 48)', '(Week 72, 96,', 'Visit', '(Week 60, 84,', '(Week 172)', '120,', '108,', 'End-of-Trial or', '144, 168)', '132, 156)', 'Early DC', 'Window', '1 week', '2 weeks', '2 weeks', '2 weeks', '2 weeks', '+ 7 days', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'Medication/Procedure Review', 'Review AEs/ADEs', 'X', 'X', 'X', 'X', 'X', 'X', 'Physical Examination', 'X', 'X', 'X', 'X', 'X', 'Vital Signsb', 'X', 'X', 'X', 'X', 'X', '12-Lead ECG\u00b0', 'X', 'X', 'X', 'X', 'X', 'C-SSRS \"Since Last Visit\"', 'X', 'X', 'X', 'X', 'X', 'Clinical chemistry and hematology', 'X', 'X', 'X', 'X', 'X', 'laboratory parametersd', 'Clinical Urinalysisd', 'X', 'X', 'X', 'X', 'X', 'Urine Pregnancy Teste', 'X', 'IMP Administration', 'X', 'Daily', 'X', 'ISR Assessment', 'X', 'X', 'X', 'X', 'a.', 'Physical examination will include: general appearance, skin, head, eyes, ears, nose, throat, neck (including thyroid), lymph nodes, chest, heart, abdomen,', 'extremities, nervous system, and weight.', 'b.', 'Vital signs will include HR, RR, and BP after sitting for 5 min, and temperature.', 'c. All scheduled ECGs must be performed after the subject has rested quietly for at least 5 min in the supine position.', 'd.', 'See Appendix 4 for clinical laboratory tests. Additional blood samples at the Early Discontinuation Visit (if applicable) will be collected and stored for', 'assessing the immunogenicity potential of the IMP.', 'e. Urine Pregnancy test will be performed for women of childbearing potential at the End-of-Trial/Early Discontinuation Visit.', 'f.', 'On days of trial visits, the IMP administered with the elamipretide delivery system should be administered at the clinical site. The location (injection in the', 'abdomen, rotating around the four abdominal quadrants, or other appropriate location [after Investigator consultation with the Sponsor]) and time (at', 'approximately the same time each day [e.g., early morning, noon, or early afternoon]) of the IMP administration will be recorded daily in a diary. Supplies', 'will be collected, compliance will be assessed, and new supplies will be provided at clinical site visits.', 'g. The skin examination should occur at 30 (+5) minutes after the IMP administration with the elamipretide delivery system. The presence and severity of pain,', 'erythema, swelling, and pruritus at the injection site will be assessed. Scoring of erythema, swelling, pruritus and pain will be done using a 5-point scale', 'using the \"Table for Grading the Severity of Site Reactions to Injections\" provided in Appendix 14.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '84']['SPIMM-301 Version 4.0', '15 June 2018', 'APPENDIX 3. TRIAL DESIGN SCHEMATIC', 'PART 1', 'Trial site(s): Multicenter (North America and Europe); approximately 27 sites', 'Elamipretide 40 mg SC daily for 24 weeks', 'Placebo SC daily for 24 weeks', 'Screening', 'Week 28 Visit (PART 1 EOT*/', 'Visit', 'Baseline Visit', 'Week 4 Visit', 'Week 12 Visit', 'Week 24 Visit', 'Early D/C Visit)', 'Screening', 'PART 1 Treatment Period', 'PART 1 Follow-Up Period', '*only applicable if subject and/or Investigator decide not to continue subject into Part 2 (SPIMM-301 OLE)', 'PART 2', 'Elamipretide 40 mg SC daily', '4 weeks', '8 weeks', '12 weeks', '28 days', 'Weeks 60, 84,', 'Week 72, 96,', 'Week 24 Visit', 'Week 28', 'Week 36', 'Week 48', '108, 132, 156', '120, 144, 168', 'Part 2 EOT/', '(PART 1)', 'Visit', 'Visit', 'Visit', '(phone call)', 'Visits', 'Early D/C Visit', 'PART 2 Treatment Period', 'Part 2 Follow-Up Period', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '85']\n\n###\n\n", "completion": "END"}